Drug Profile
TSK 204
Latest Information Update: 30 Jul 2002
Price :
$50
*
At a glance
- Originator Kyowa Hakko; Taisho Pharmaceutical
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatic disorders
Most Recent Events
- 22 Feb 2000 New profile
- 22 Feb 2000 Preclinical development for Rheumatic disorders in Japan (Unknown route)